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beneﬁts of introducing the 7-valent pneumococcal conjugate vaccine
(PCV7) into the City Immunity Program in Shanghai. Methods:
A decision-analytic model designed for pneumococcal disease and
outcomes of pneumococcal infection was populated with local, age-
speciﬁc incidence and cost data to estimate the expected economic
beneﬁts from vaccinating a birth cohort of 172,183 infants in Shanghai
over a 1-year period using a cross-sectional approach. The analysis
was assumed to occur in a year at which time the direct and indirect
effects of vaccination have reached a steady state. Costs were
calculated from a payer perspective and included vaccination pro-
gram costs and direct medical expenditures from pneumococcal-
related disease. Results: The model predicts that 112,629 cases of
pneumococcal-related disease could be prevented during a given year
following the introduction of the PCV7 vaccine into the City Immunityee front matter Copyright & 2014, International S
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ndence to: Shan Lian Hu, Shanghai Health DevelopProgram in Shanghai, leading to a reduction of ¥187,923,359 (US
$29,067,790) in direct medical costs. Overall, the inclusion of the PCV7
vaccine is estimated to have a cost-per-life-year saved of ¥37,468 (US
$5,796) and a cost-per-quality-adjusted-life-year gained of ¥41,603 (US
$6,435) when both the direct and indirect effects of the vaccine resulting
from herd protection are taken into account. Conclusions: Results
suggest that including PCV7 into the City Immunity Program in Shang-
hai could be considered cost-effective under generally accepted
willingness-to-pay thresholds when both the direct and indirect effects
of the vaccine are considered in the analysis.
Keywords: cost-effectiveness, herd immunity, PCV7, pneumococcal
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Streptococcus pneumoniae, which can result in both invasive dis-
eases, such as bacteremic pneumonia, septicemia, and meningi-
tis, and noninvasive diseases, such as pneumonia, otitis media,
and sinusitis infections, is a leading cause of respiratory disease
globally. One of the key risk factors for pneumococcal disease is
age, with children younger than 5 years and the elderly being at
the highest risk of developing pneumococcal-related infection.
Pneumococcal disease is estimated to be the leading cause of
vaccine-preventable morbidity and mortality among children
younger than 5 years both globally and in China [1,2]. The World
Health Organization has reported that approximately 1.6 million
people die each year from pneumococcal-related diseases.
Among this group, approximately 700,000 to 1 million are chil-
dren younger than 5 years [3]. In addition to the mortality
associated with pneumococcal-related diseases, there exists a
signiﬁcant effect on the overall quality of life among thoseinﬂicted with the disease, as well as a large economic burden
for both patients and society.
The 7-valent pneumococcal conjugate vaccine (PCV7) was
licensed for use in the United States in February 2000 and was
subsequently recommended for routine vaccination of all infants
in the United States starting at age 2 months [4]. Since its addition
to the recommended vaccination schedule, the vaccine has had a
dramatic effect on the incidence of pneumococcal-related disease
due largely to the indirect effect from herd protection on unvacci-
nated children and adults [5,6]. A report by the Centers for Disease
Control and Prevention indicates that most of the reduction in
invasive pneumococcal disease (IPD) cases following the intro-
duction of PCV7 into the routine vaccination schedule among
infants in the United States was due to the indirect effect on the
unvaccinated population by reducing the nasopharyngeal carriage
of Streptococcus pneumoniae among immunized children [7].
The PCV7 vaccine contains seven serotypes: 4, 6B, 9 V, 14, 18C,
19 F, and 23 F. Although there are more than 90 knownociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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most of the pneumococcal-related disease globally [8,9], and it is
estimated that the serotypes contained in the PCV7 vaccine
would account for approximately 76% of the serotypes associated
with pneumococcal disease prevalent among children younger
than 5 years in China [10]. As a result of both the impressive
safety and effectiveness record of the PCV7 vaccine in the United
States and elsewhere over the past decade, the World Health
Organization has recommended the inclusion of PCV7 in child-
hood immunization programs worldwide [11].
Although there have been a number of studies demonstrating
the cost-effectiveness of introducing PCV7 into the national immu-
nization programs of various countries in Asia [12–17], there has not
yet been an analysis of the potential economic effect of adding PCV7
to the routine childhood vaccination schedule in China. In this
study, for several reasons, we focus attention on PCV7 rather than
alternative, higher valency versions of the pneumococcal vaccine. At
the time of this writing, PCV7 is the only pneumococcal conjugate
vaccine that is approved for use in China, and it is currently listed as
a type 2 vaccine on the Expanded Program Immunization, making it
nonmandatory and not reimbursed [18,19]. Furthermore, higher
valency pneumococcal vaccines, such as the 13-valent pneumo-
coccal conjugate vaccine, are unlikely to be available in China before
2016. To estimate the effect of PCV7 in China, this study applies
demographic, epidemiological, and medical cost data from local and
regional sources to amathematical model designed to estimate both
the clinical and economic beneﬁts of the PCV7 vaccine, and
incorporates both the direct effect of the vaccine on children in
Shanghai and the indirect effects of herd protection on the unvacci-
nated child and adult population. Given the lack of availability of
higher valency versions of the pneumococcal conjugate vaccine in
China, it would be difﬁcult to effectively populate the model with
local, Chinese-speciﬁc data necessary for a relevant evaluation of
the effect of the vaccine in a Chinese population setting. In addition,
given that PCV7 is not currently in widespread use in China, it is
particularly relevant that many regional, Asian-speciﬁc studies have
focused on PCV7, providing a set of relevant references with which
our results can be suitably compared.Methods
Model Structure
To estimate outcomes associated with various vaccination strat-
egies, a previously developed decision-analytic model designed for
pneumococcal disease and outcomes of pneumococcal infection
[20] was adapted to estimate the health outcomes from including
the PCV7 vaccine into the routine vaccination schedule for a birth
cohort of infants in Shanghai using a cross-sectional analysis over
a 1-year period. The clinical starting point of the model is the
vaccination strategy, comparing the case of no vaccinations to a
case in which the vaccination coverage level is 85% for all newly
born infants in Shanghai. Vaccine administration for the birth
cohort occurs with a primary series of three doses in the ﬁrst 6
months and a booster dose at age 12 months. Individuals within
the model had a probability of contracting invasive pneumococcal
disease (bacteremia and meningitis), all-cause pneumonia, or all-
cause otitis media. Outcomes were calculated over a 1-year period
that was assumed to occur at a point at which the vaccine effects
had reached a steady state, approximately 5 to 7 years after the
introduction of the vaccine. Disease cases were estimated on the
basis of disease incidence, serotype coverage, and both the direct
effect of the vaccine and the indirect effect from herd protection
on the unvaccinated population.
Estimates of the Shanghai population by age for 2011 are
based on data from the 6th Population Survey of Shanghai [21].The population within the model is broken up into seven age
groups (o2, 2–4, 5–17, 18–34, 35–49, 50–64, and 65þ y). All children
in the model younger than 5 years are considered to have been
vaccinated in previous periods. The birth cohort, consisting of all
children in the model younger than 12 months, is assumed to
receive the infant series and booster dose in the current period
with a vaccine coverage rate of 85%. This level of vaccine cover-
age is consistent with observed levels of coverage in the United
States [22] and is therefore considered a more appropriate level of
coverage expectation than the standard universal coverage
hypothesis often used in similar analyses of vaccine cost-
effectiveness studies. Based on population estimates for 2011,
this incoming birth cohort is considered to be 0.88% of the total
population of Shanghai, or approximately 202,568 individuals
[21]. All children aged 5 years or older and adults are considered
unvaccinated during all stages in the model.
Outcomes are assessed as a cross-sectional analysis over a 1-
year period, which was assumed to occur after the vaccine
effects have reached a steady state, for the entire population of
Shanghai to capture both the direct beneﬁts for the vaccinated
population and the indirect beneﬁts of herd protection among the
unvaccinated. The disease states incorporated into the model
include invasive pneumococcal disease (bacteremia and menin-
gitis), all-cause pneumonia (inpatient and outpatient), and all-
cause otitis media (mild, and moderate to severe). Disease states
within the model are not mutually exclusive, so it is considered
possible for individuals to experience multiple pneumococcal-
related outcomes during the annual cycle. The model calculates
the number of estimated pneumococcal infections for each age
grouping and the anticipated mortality associated with these
events.
Cost inputs included in the model and the cost-effectiveness
results were calculated from a payer perspective. The cost data
within the model include both the direct medical costs of treat-
ment for each disease state and age group and the cost of the
vaccine per dose and the direct cost associated with administer-
ing the vaccine. The cost-effectiveness outcomes calculated
include cost-per-life-year saved, cost-per-quality-adjusted-life-
year (QALY) gained, and cost-per-illness avoided. All cost data
are reported using 2011 Chinese yuan, consistent with the source
of the cost data incorporated in the model, and discounted at
5.0% per year. Cost-effectiveness outcomes are also reported in U.
S. dollars using exchange rates as of July 2011 [23] to facilitate
comparisons with previously published cost-effectiveness stud-
ies on the PCV7 vaccine from other countries.Model Parameters and Input Data
Disease Incidence and Case-Fatality Rates
Baseline age-speciﬁc disease incidence rates and case-fatality
rates for disease states included in the model are reported in
Table 1. Because China does not ofﬁcially require reporting of IPD
cases, it is difﬁcult to obtain accurate epidemiologic data regard-
ing IPD incidence in China. As a result, the baseline incidence
data and case mortality rates for IPD and all-cause pneumonia
were based on estimates from the Taiwan National Health
Insurance Administration for the years 2002 to 2007 [24]. The
incidence rates for each age group were calculated as the number
of observed morbidity cases per 100,000 population to provide the
estimated baseline incidence rate. Case-fatality rates for each age
group were calculated as the probability of death conditional on
having a pneumococcal-related disease by age group. It is also
assumed in the model that long-term sequelae can result from
meningitis infection. The model assumes, on the basis of pub-
lished sources, that approximately 13% of meningitis survivors
Table 1 – Baseline disease incidence and case-fatality rates.
Parameter Age group (y)
0–o2 2–4 5–17 18–34 35–49 50–64 65þ
Annual baseline incidence rates/100,000
Pneumococcal bacteremia 3.81 3.80 0.22 0.18 0.36 0.82 4.47
Pneumococcal meningitis 1.48 0.53 0.11 0.04 0.04 0.08 0.14
Clinically diagnosed inpatient pneumonia (all-
cause)
4,624.58 3,884.29 458.62 104.00 118.00 367.20 2,848.50
Clinically diagnosed outpatient pneumonia
(all-cause)
31,632.72 38,108.78 6,272.27 1,516.20 1,814.10 2,967.10 10,007.89
Otitis media (mild) 15,866.10 17,278.56 3,978.31 1,247.30 1,528.20 1,892.10 2,085.22
Otitis media (moderate/severe) 6,893.74 6,201.94 889.07 133.70 252.00 342.50 361.23
Case-fatality rates (%)
Pneumococcal bacteremia 4.0 1.0 5.0 5.0 6.0 6.0 6.0
Pneumococcal meningitis 14.0 3.0 4.0 0.0 12.0 0.0 2.0
Clinically diagnosed inpatient pneumonia 0.0 0.0 0.0 6.0 6.0 10.0 16.0
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will result in other long-term disabilities [25–27].Vaccine Effectiveness
The model incorporates both the direct effect of disease reduc-
tion among vaccinated children and the indirect effect on adults
and unvaccinated children as a result of herd protection. Esti-
mates of these effects on IPD (pneumococcal bacteremia and
pneumococcal meningitis), all-cause pneumonia (inpatient and
outpatient), and otitis media (mild, and moderate to severe) are
presented in Table 2.
The direct effectiveness of the vaccine in terms of percent
reduction in disease incidence following vaccination was derived
from clinical data measuring the effect of PCV7 on the reduction
of IPDs as measured by the immune response of healthy children
observed in a clinical trial. The efﬁcacy of the vaccine in Chinese
children, as assessed by immunologic response 30 to 50 days
following the primary immunization series, was found to be
similar to that in children in the United States [28], so U.S. data
from published sources on the direct effectiveness of the vaccine
on the percent reduction in disease at the time of vaccination
was used for model estimation [27].Table 2 – Estimated direct and indirect effects of PCV7.
Parameter
0–o2
Direct effects (% reduction in disease at time of vaccination)
Pneumococcal bacteremia 94
Pneumococcal meningitis 94
Clinically diagnosed inpatient pneumonia (all-cause) 26
Clinically diagnosed outpatient pneumonia (all-cause) 6
Otitis media (mild) 7
Otitis media (moderate/severe) 0
Indirect effects (% reduction in disease)
Pneumococcal bacteremia 47
Pneumococcal meningitis 47
Clinically diagnosed inpatient pneumonia (all-cause) 30
Clinically diagnosed outpatient pneumonia (all-cause) 8
Otitis media (mild) 20
Otitis media (moderate/severe) 19
PCV7, 7-valent pneumococcal conjugate vaccine.Based on vaccine sales information, the current vaccination
rate of PCV7 for children younger than 2 years in China is less than
10%. As a result, the vaccination rate in China is not high enough to
achieve a herd immunity effect necessary to estimate the indirect
effect of PCV7 vaccination at an 85% level of coverage on the
unvaccinated population in China. Data on the percent reduction
in pneumococcal disease incidence among the unvaccinated pop-
ulation is therefore derived from research done in the United
States following the introduction of the PCV7 vaccine into the
routine childhood vaccination schedule in the United States [29].Cost Data
Cost data for direct medical cost per case of pneumococcal-related
disease by age group and costs related to the vaccination of the
incoming birth cohort used in the model are reported in Table 3.
Local inpatient cost data on directmedical costs related to pneumo-
coccal disease were collected from de-identiﬁed case records from
the Shanghai Board of Health Central Information Data Base. This
database lists inpatient disease type and expense information from
hospitals in Shanghai. The cost data are for conﬁrmed inpatient
cases of pneumococcal meningitis, pneumococcal bacteremia, and
all-cause pneumonia reported from January to December 2011. TheAge group (y)
2–4 5–17 18–34 35–49 50–64 65þ
94 – – – – –
94 – – – – –
26 – – – – –
6 – – – – –
7 – – – – –
0 – – – – –
40 18 49 33 17 34
40 18 49 33 17 34
9 9 13 11 9 8
8 5 6 7 4 4
0 0 0 0 0 0
0 0 0 0 0 0
Table 3 – Costs* used in the model.
Parameter Age group (y)
0–o2 2–4 5–17 18–34 35–49 50–64 65þ
Direct medical cost per case
Pneumococcal bacteremia 24,347 14,805 24,660 17,707 25,942 21,331 34,495
Pneumococcal meningitis 24,347 14,805 24,660 17,707 25,942 21,331 34,495
Clinically diagnosed inpatient pneumonia (all-cause) 4,416 2,466 2,867 6,775 9,698 10,517 14,493
Clinically diagnosed outpatient pneumonia (all-cause) 152 188 238 726 726 726 1,021
Otitis media (mild) 205 150 195 232 232 232 300
Otitis media (moderate/severe) 91 122 129 221 221 221 275
Vaccine cost
PCV7 vaccine (per dose) 860 – – – – – –
Estimated vaccine administrative cost (per dose) 10 – – – – – –
Number of doses 4 – – – – – –
Total direct vaccination costs per infant 3,480 – – – – – –
PCV7, 7-valent pneumococcal conjugate vaccine.
* All values measured in 2011 Chinese yuan.
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consultation fees, diagnostic tests, operation fees, nursing fees,
and medication expenses. Costs by disease type and age group
were calculated as the total direct medical expenses for all
individuals within that age group during 2011 divided by the total
number of patients within that age group.
The costs associated with the vaccination program include the
cost per dose of the vaccine and estimated administration costs.
The average price for the PCV7 vaccine was assumed to be ¥860 per
dose on the basis of published vaccine prices in Shanghai [18]. Each
vaccinated infant is assumed to receive four doses over the course
of the year so that the total vaccine cost per vaccinated infant was
estimated to be ¥3440. In addition to the cost of the vaccine, an
administration cost of ¥10 per dose was assumed so that the total
direct medical cost of vaccination, vaccine cost and administration,
for each infant vaccinated within the model was ¥3480.
Cost-Effectiveness Analysis
The model generates estimates for each vaccination strategy over
an annual cycle, yielding estimates for the number of pneumococcal
disease cases, number of deaths related to pneumococcal disease,
number of life-years saved, and the number of QALYs gained. Life-
years saved as a result of deaths avoided were calculated as the
average life expectancies remaining for each age group estimated
from life tables for China derived from World Health Organization
estimates [30]. These average life expectancies by age group were
80.8 years for ages 0 to 2 years, 77.0 years for ages 2 to 4 years, 65.5
years for ages 5 to 17 years, 51.1 years for ages 18 to 34 years, 36.8
years for ages 35 to 49 years, 23.3 years for ages 50 to 64 years, and
9.0 years for ages 65 years and above. QALYs gained were calculated
on the basis of the number of life-years spent in each health state
multiplied by the associated health state utility weight. The utility
weights used in the model for neurological impairment and hearing
loss resulting from meningitis and the health utility index were
obtained from published sources [31,32]. Incremental cost-
effectiveness ratios were calculated by taking the ratio between
the difference in costs and the difference in outcomes.Results
Outcomes
The estimated number of pneumococcal-related disease cases,
pneumococcal-related deaths, life-years lost, and QALYs lostpredicted by the model for both the no-vaccination strategy and
the use of PCV7 are reported in Table 4. Also included in Table 4
are the estimated, differential effects on each of these health
outcomes resulting from the inclusion of the PCV7 vaccine into the
City Immunity Program in Shanghai. The model predicts that the
direct effect of including the PCV7 vaccine into the routine
vaccination schedule would result in a reduction in the number
of pneumococcal disease cases among the vaccinated population
by 29,433 during a given year once vaccine steady state has been
achieved. Among these are 7,190 cases of hospitalizations resulting
from pneumococcal infection, caused by bacteremia, meningitis,
or all-cause pneumonia among children younger than 5 years.
When the indirect effects of vaccination due to herd protection
among the unvaccinated population are also considered, the total
number of pneumococcal-related disease cases prevented
increases to 112,629.
Costs
Estimated costs, measured in 2011 Chinese yuan, from
pneumococcal-related disease and vaccination strategy are reported
in Table 5. The model estimates that the inclusion of the PCV7
vaccine into the routine vaccination schedule in Shanghai would
result in a reduction of approximately ¥28,036,721 in direct medical
care expenses among the vaccinated population. When the addi-
tional effect on the unvaccinated population is taken into account,
this ﬁgure rises to a total level of savings of ¥187,923,359 in medical
care expenses associated with treatment for pneumococcal-related
diseases during the initial year following the implementation of the
vaccination policy. The direct vaccination program costs were
estimated to be ¥599,198,880 for the incoming birth cohort. Most
of this was due to the cost of the actual vaccine. The sum of both
the changes in direct medical expenses for the treatment of
pneumococcal-related disease and the direct costs of the vaccina-
tion program resulted in a total cost increase of ¥411,275,520.
Cost-Effectiveness
The incremental cost-effectiveness ratios for the model are pre-
sented in Table 6. When including only the beneﬁts accruing to the
vaccinated cohort, the results show a cost-per-life-year saved ratio
of ¥2,230,979 (US $345,086) and a cost-per-QALY gained of ¥2,434,054
(US $376,497). When adding the indirect beneﬁts from the unvacci-
nated children and adults due to herd protection, however, the cost-
per-life-year saved ratio becomes ¥37,468 (US $5,796) and the cost-
per-QALY gained becomes ¥41,603 (US $6,435).
Table 5 – Estimated cost* of pneumococcal disease and vaccination.
Cost No vaccine (a) PCV7 (b) Difference (b – a)
Direct costs only
Total medical costs 2,106,033,292 2,077,996,571 28,036,721
Vaccination costs 0 599,198,880 599,198,880
Total costs 2,106,033,292 2,677,195,450 571,162,158
Direct and indirect costs
Total medical costs 2,106,033,292 1,918,109,933 187,923,359
Vaccination costs 0 599,198,880 599,198,880
Total costs 2,106,033,292 2,517,308,812 411,275,520
PCV7, 7-valent pneumococcal conjugate vaccine.
* All values measured in 2011 Chinese yuan.
Table 4 – Estimated outcomes: Cases, deaths, life-years, and quality-adjusted life-years for direct and total
effects.
Direct effect only Total effect (direct þ indirect)
Direct effect only No vaccine (a) PCV7 (b) Difference (b  a) No vaccine (a) PCV7 (b) Difference (b – a)
Pneumococcal bacteremia
Cases (all age groups) 124 105 19 124 72 52
0–4 y 23 4 19 23 3 20
5þ y 101 101 0 101 69 32
Pneumococcal meningitis
Cases (all age groups) 14 9 5 14 6 8
0–4 y 6 1 5 6 1 5
5þ y 8 8 0 8 5 3
Inpatient pneumonia
Cases (all age groups) 139,205 132,039 7,166 139,205 118,067 21,138
0–4 y 33,059 25,893 7,166 33,059 21,272 11,787
5þ y 106,146 106,146 0 106,146 96,795 9,351
Outpatient pneumonia
Cases (all age groups) 980,476 966,113 14,363 980,476 910,269 70,207
0–4 y 281,643 267,280 14,363 281,643 245,897 35,746
5þ y 698,833 698,833 0 698,833 664,372 34,461
Otitis media (mild)
Cases (all age groups) 520,551 512,671 7,880 520,551 503,397 17,154
0–4 y 132,433 124,553 7,880 132,433 115,279 17,154
5þ y 388,118 388,118 0 388,118 388,118 0
Otitis media (moderate/severe)
Cases (all age groups) 115,242 115,242 0 115,242 111,171 4,071
0–4 y 51,261 51,261 0 51,261 47,190 4,071
5þ y 63,981 63,981 0 63,981 63,981 0
Total cases (all age groups) 1,755,611 1,726,179 29,432 1,755,611 1,642,982 112,629
0–4 y 498,424 468,992 29,432 498,424 429,642 68,782
5þ y 1,257,187 1,257,187 0 1,257,187 1,213,340 43,847
Deaths
Cases (all age groups) 13,236 13,223 13 13,236 12,110 1,126
0–4 y 55 42 13 55 32 23
5þ y 13,181 13,181 0 13,181 12,078 1,103
Life-years lost
Cases (all age groups) 121,443 121,187 256 121,443 110,466 10,977
0–4 y 1,120 864 256 1,120 649 471
5þ y 120,323 120,323 0 120,323 109,817 10,506
QALYs lost
Cases (all age groups) 109,310 109,076 234 109,310 99,425 9,885
0–4 y 1,013 779 234 1,013 585 428
5þ y 108,297 108,297 0 108,297 98,840 9,457
PCV7, 7-valent pneumococcal conjugate vaccine; QALY, quality-adjusted life-year.
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Table 6 – Incremental cost-effectiveness results of
PCV7 vaccination relative to no vaccination*.
Cost per unit Direct effect
only
Total effect (direct þ
indirect)
Cost-per-life-
year saved
2,230,979 (US
$345,086)
37,468 (US $5,796)
Cost-per-QALY
gained
2,434,054 (US
$376,497)
41,603 (US $6,435)
Cost-per-illness
avoided
19,406 (US
$3,002)
3,652 (US $565)
PCV7, 7-valent pneumococcal conjugate vaccine; QALY, quality-
adjusted life-year.
* All values measured in 2011 Chinese yuan. July 2011 exchange
rate, US $1 ¼ ¥6.465 [21].
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A series of univariate sensitivity analyses were performed to test
the sensitivity of the results to several key data input parameters.
The ranges of the parameters selected correspond to previously
published articles on the cost-effectiveness of PCV7 in other
countries in Asia. This analysis was performed on the vaccine
cost (25% of base case) [16], vaccine coverage level (10% of
base case) [13], vaccine serotype coverage (5% of base-case
values) [13,15], and the percent reduction in disease incidence
for the indirect effect in the model (5% of the base-case
incidence reduction values). The results of the sensitivity analy-
ses are reported in Table 7. All incremental cost-effectiveness
values shown include both the direct effect and the indirect effect
of the vaccine.
The model results were the least sensitive to changes in the
vaccine serotype coverage, with a range of ¥44 (US $7) between
the high and low values considered in the analysis for the cost-
per-life-year saved measure. Alterations in vaccine price and
vaccine coverage rate showed slightly higher variation, with
ranges for the cost-per-life-year-saved measure of ¥29,958
(US $4,634) and ¥12,209 (US $1,889), respectively. In all cases,
the results remained highly cost-effective and were consistent
with previously published results from other countries in Asia
[13,15,16]. The cost-effectiveness outcomes were most sensitive
to changes in the percent reduction in disease incidence among
the unvaccinated population, with a cost-per-life-year saved
range of ¥84,041 (US $12,999).Discussion
Several studies have examined both the clinical and economic
beneﬁts of the PCV7 vaccine in various countries around theTable 7 – Sensitivity analysis.
Parameter varied Range of
values
Base case (with indirect effects) NA
Vaccine price 645–1,075 (25%)
Vaccine coverage level 75%–95%
Vaccine serotype coverage 5%
Indirect effects (% reduction in disease
incidence)
5%
Note. All values measured in 2011 Chinese yuan. July 2011 exchange rate
NA, not applicable; QALY, quality-adjusted life-year.world, but there has yet to be a study that addresses the cost-
effectiveness of including PCV7 into the routine vaccination
schedule in China using local economic and epidemiological
data. This study bridges that gap by applying data on disease
outcomes and direct medical costs from local and regional
sources to a mathematical model designed to estimate the public
health impact and the cost-effectiveness of the pneumococcal
vaccine by incorporating both the direct effect on vaccinated
children and the indirect effect of herd protection on unvacci-
nated children and adults in Shanghai.
According to the World Health Organization’s pharmacoeco-
nomic evaluation criteria, if the incremental cost-effectiveness ratio
is found to be within three times the average per-capita income of
that region, then the intervention would be considered cost-
effective [33]. The 2011 per capita yearly income of Shanghai was
estimated to be ¥82,560 (US $12,770) [34]. When the direct effect of
introducing the PCV7 vaccine into the routine vaccination schedule
in Shanghai alone is considered, the results suggest that the
intervention would not be regarded as cost-effective under
that guideline. Our study yields values for incremental cost-
effectiveness ratios (cost-per-life-year saved and cost-per-QALY
gained) that are substantially higher than the thresholds estab-
lished by the World Health Organization as the appropriate cutoff
for considering a health intervention to be cost-effective to imple-
ment. When the full effect of the vaccine on both the vaccinated
population and the unvaccinated population is considered, how-
ever, then the resulting cost-effectiveness ratios are 45.4% and
50.4% of the 2011 per-capita income in Shanghai for the cost-per-
life-year saved and cost-per-QALY gained measures, respectively,
which is within the acceptable threshold to be considered a cost-
effective intervention.
The indirect effects resulting from herd immunity are the
major driver of the cost-effectiveness of the PCV7 vaccine in this
study. Indirect effects account for approximately 73.9% of the
disease cases prevented, 98.8% of the lives saved, and 97.7% of
the life-years gained as a result of the inclusion of the vaccine.
The evidence supporting the existence of this effect and its
impact has been growing over the decade since the introduction
of the PCV7 vaccine into the routine vaccination schedule in the
United States [5,7,35].
Our results, suggesting the importance of the indirect effects
in determining the cost-effectiveness of the vaccine, are largely
in line with other cost-effectiveness studies of PCV7 on popula-
tions in Asia incorporating both direct and indirect effects of herd
protection on the unvaccinated population. A study for Malaysia
found a cost-per-life-year saved ratio of $10,261 when both the
direct and indirect effects from herd immunity on the adult
population were included in the analysis [13]. A study for Taiwan
found a cost-per-life-year gained ratio of $474,034 when only
direct effects were included and a ratio of $37,155 when both
direct and indirect effects were incorporated into the analysisCost-per-life-year
saved (US$)
Cost-per-QALY
gained (US$)
37,468 (US $5,796) 41,603 (US $6,435)
26,624–56,582 (US $4,118–8,752) 23,978–50,958 (US $3,708–7,882)
31,351–43,560 (US $4,849–6,738) 34,812–48,366 (US $5,384–7,481)
37,446–37,490 (US $5,792–5,799) 41,577–41,629 (US $6,431–6,439)
18,031–102,072 (US $2,789–
15,788)
20,025–113,254 (US $3,097–
17,518)
, US $1 ¼ ¥6.465 [21].
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would be $231,971 without considering herd protection and
$43,275 when herd protection was incorporated [16]. In Hong
Kong, an analysis of the introduction of universal vaccination
with PCV7 among infants over a 10-year time horizon that also
included both direct and indirect effects resulted in a cost-per-
life-year gained ratio of $6460 [15]. In studies in which the results
without the inclusion of herd protection were reported, the cost-
effectiveness ratios suggest that vaccination with PCV7 would
not be considered cost-effective. In all cases in which both direct
and indirect effects were incorporated into the analysis, however,
the results were found to be cost-effective based on World Health
Organization guidelines [32].
The study, as implemented, is subject to a number of qual-
iﬁcations due to the lack of data speciﬁc to the target population.
China does not ofﬁcially require reporting of IPD cases, so it is
difﬁcult to derive incidence and case-fatality rates for
pneumococcal-related diseases using local Chinese data. To
derive the incidence and mortality data used in the model
required the combining of data from various sources. IPD inci-
dence and mortality data were collected from the Taiwan
National Health Insurance Administration for the years 2002 to
2007, the PCV7 effectiveness data were derived from publicly
available references and some organizational internal archival
data, and the demographic data were collected from the 6th
Population Survey of Shanghai. The authors note that the process
of interpreting and synthesizing data derived from such a variety
of sources is subject to potential bias. It also should be noted that
population factors such as population density may differ signiﬁ-
cantly across regions. It is likely that in a city as densely
populated as Shanghai that the use of epidemiological data from
sources derived from other regions may not accurately reﬂect the
degree of disease transmission present in Shanghai. Given the
infectious nature of pneumococcal disease, it is plausible that the
indirect effects estimated in this study may differ from the
realized indirect effects. As demonstrated in the sensitivity
analysis, the model results are particularly sensitive to changes
in the indirect effects on disease incidence among the unvacci-
nated population. If this study is underestimating the effect of
herd protection, then the actual cost-effectiveness outcomes may
be considerably lower than our base-case estimates would
suggest.Conclusions
Currently, the PCV7 vaccine is not included in the routine
vaccination schedule in China. The results of this study suggest
that, for Shanghai, the inclusion of the PCV7 vaccine into the
routine vaccination schedule for children would result in a
substantial reduction in the number of pneumococcal-related
diseases and deaths, particularly among the unvaccinated adult
population because of the existence of herd protection. At the
population level, the vaccine is found to be cost-effective
based on the World Health Organization’s threshold for cost-
effectiveness and would, therefore, likely be a worthwhile inclu-
sion into the City Immunity Program in Shanghai.
Source of ﬁnancial support: Pﬁzer Investment Co. Ltd. sup-
ported this study.
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